Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, April 2002, p. 977-981, Vol. 46, No. 4
0066-4804/02/$04.00+0 DOI: 10.1128/AAC.46.4.977-981.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705
Y. Furuta,1* K. Takahashi,1 Y. Fukuda,1 M. Kuno,1 T. Kamiyama,1 K. Kozaki,1 N. Nomura,1 H. Egawa,1 S. Minami,1 Y. Watanabe,1 H. Narita,1 and K. Shiraki2
Research Laboratories, Toyama Chemical Co., Ltd., 2-4-1 Shimookui,1
Department of Virology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama, Japan2
Received 29 June 2001/
Returned for modification 10 September 2001/
Accepted 27 December 2001
T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) has been found to have potent and selective inhibitory activity against influenza virus. In an in vitro plaque reduction assay, T-705 showed potent inhibitory activity against influenza A, B, and C viruses, with 50% inhibitory concentrations (IC50s) of 0.013 to 0.48 µg/ml, while it showed no cytotoxicity at concentrations up to 1,000 µg/ml in Madin-Darby canine kidney cells. The selectivity index for influenza virus was more than 2,000. It was also active against a neuraminidase inhibitor-resistant virus and some amantadine-resistant viruses. T-705 showed weak activity against non-influenza virus RNA viruses, with the IC50s being higher for non-influenza virus RNA viruses than for influenza virus, and it had no activity against DNA viruses. Orally administered T-705 at 100 mg/kg of body weight/day (four times a day) for 5 days significantly reduced the mean pulmonary virus yields and the rate of mortality in mice infected with influenza virus A/PR/8/34 (3 x 102 PFU). These results suggest that T-705 may be a compound that is useful and highly selective against influenza virus infections and that has a mode of action different from those of commercially available drugs, such as amantadine, rimantadine, and neuraminidase inhibitors.
* Corresponding author. Mailing address: Research Laboratories, Toyama Chemical Co., Ltd., 2-4-1 Shimookui, Toyama, 930-8508, Japan. Phone: 81-76-431-8257. Fax: 81-76-431-8208. E-mail:
YOUSUKE_FURUTA{at}toyama-chemical.co.jp.
Antimicrobial Agents and Chemotherapy, April 2002, p. 977-981, Vol. 46, No. 4
0066-4804/02/$04.00+0 DOI: 10.1128/AAC.46.4.977-981.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Smee, D. F., Hurst, B. L., Egawa, H., Takahashi, K., Kadota, T., Furuta, Y.
(2009). Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemother
64: 741-746
[Abstract]
[Full Text]
-
Julander, J. G., Shafer, K., Smee, D. F., Morrey, J. D., Furuta, Y.
(2009). Activity of T-705 in a Hamster Model of Yellow Fever Virus Infection in Comparison with That of a Chemically Related Compound, T-1106. Antimicrob. Agents Chemother.
53: 202-209
[Abstract]
[Full Text]
-
Gowen, B. B., Wong, M.-H., Jung, K.-H., Sanders, A. B., Mendenhall, M., Bailey, K. W., Furuta, Y., Sidwell, R. W.
(2007). In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus Infections. Antimicrob. Agents Chemother.
51: 3168-3176
[Abstract]
[Full Text]
-
Julander, J. G., Furuta, Y., Shafer, K., Sidwell, R. W.
(2007). Activity of T-1106 in a Hamster Model of Yellow Fever Virus Infection. Antimicrob. Agents Chemother.
51: 1962-1966
[Abstract]
[Full Text]
-
Sidwell, R. W., Barnard, D. L., Day, C. W., Smee, D. F., Bailey, K. W., Wong, M.-H., Morrey, J. D., Furuta, Y.
(2007). Efficacy of Orally Administered T-705 on Lethal Avian Influenza A (H5N1) Virus Infections in Mice. Antimicrob. Agents Chemother.
51: 845-851
[Abstract]
[Full Text]
-
Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Nomura, N., Egawa, H., Shiraki, K.
(2005). Mechanism of Action of T-705 against Influenza Virus. Antimicrob. Agents Chemother.
49: 981-986
[Abstract]
[Full Text]
-
McSharry, J. J., McDonough, A. C., Olson, B. A., Drusano, G. L.
(2004). Phenotypic Drug Susceptibility Assay for Influenza Virus Neuraminidase Inhibitors. CVI
11: 21-28
[Abstract]
[Full Text]